Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
about
Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes.New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement.Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASHThe Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes
P2860
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
@en
type
label
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
@en
prefLabel
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
@en
P2093
P2860
P1476
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
@en
P2093
Paolo Pozzilli
Rossella Del Toro
Stefan Rhys Williams
P2860
P304
P356
10.1080/14712598.2016.1180363
P407
P577
2016-05-04T00:00:00Z